Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. by Urowitz, MB et al.
UC San Diego
UC San Diego Previously Published Works
Title
Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus 
in the systemic lupus international collaborating clinics cohort.
Permalink
https://escholarship.org/uc/item/5zx1979k
Journal
Lupus science & medicine, 3(1)
ISSN
2053-8790
Authors
Urowitz, MB
Gladman, DD
Anderson, NM
et al.
Publication Date
2016
DOI
10.1136/lupus-2015-000143
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Cardiovascular events prior to or early
after diagnosis of systemic lupus
erythematosus in the systemic
lupus international collaborating
clinics cohort
M B Urowitz,1 D D Gladman,1 N M Anderson,1 J Su,1 J Romero-Diaz,2 S C Bae,3
P R Fortin,4 J Sanchez-Guerrero,1 A Clarke,5 S Bernatsky,6 C Gordon,7 J G Hanly,8
D J Wallace,9 D Isenberg,10 A Rahman,10 J Merrill,11 E Ginzler,12 G S Alarcón,13
B F Fessler,13 M Petri,14 I N Bruce,15,16 M Khamashta,17 C Aranow,18 M Dooley,19
S Manzi,20 R Ramsey-Goldman,21 G Sturfelt,22 O Nived,22 K Steinsson,23
A Zoma,24 G Ruiz-Irastorza,25 S Lim,26 K C Kalunian,27 M In̉anç,28
R van Vollenhoven,29 M Ramos-Casals,30 D L Kamen,31 S Jacobsen,32
C Peschken,33 A Askanase,34 T Stoll35
To cite: Urowitz MB,
Gladman DD, Anderson NM,
et al. Cardiovascular events
prior to or early after
diagnosis of systemic lupus
erythematosus in the
systemic lupus international
collaborating clinics cohort.
Lupus Science & Medicine
2016;3:e000143.
doi:10.1136/lupus-2015-
000143
Received 18 December 2015
Revised 18 March 2016
Accepted 23 March 2016
For numbered affiliations see
end of article.
Correspondence to
Dr Murray B Urowitz;
m.urowitz@utoronto.ca
ABSTRACT
Objective: To describe the frequency of myocardial
infarction (MI) prior to the diagnosis of systemic lupus
erythematosus (SLE) and within the first 2 years of
follow-up.
Methods: The systemic lupus international
collaborating clinics (SLICC) atherosclerosis inception
cohort enters patients within 15 months of SLE
diagnosis. MIs were reported and attributed on a
specialised vascular event form. MIs were confirmed
by one or more of the following: abnormal ECG, typical
or atypical symptoms with ECG abnormalities and
elevated enzymes (≥2 times upper limit of normal), or
abnormal stress test, echocardiogram, nuclear scan or
angiogram. Descriptive statistics were used.
Results: 31 of 1848 patients who entered the cohort
had an MI. Of those, 23 patients had an MI prior to
SLE diagnosis or within the first 2 years of disease.
Of the 23 patients studied, 60.9% were female, 78.3%
were Caucasian, 8.7% black, 8.7% Hispanic and 4.3%
other. The mean age at SLE diagnosis was 52.5
±15.0 years. Of the 23 MIs that occurred, 16 MIs
occurred at a mean of 6.1±7.0 years prior to diagnosis
and 7 occurred within the first 2 years of follow-up.
Risk factors associated with early MI in univariate
analysis are male sex, Caucasian, older age at
diagnosis, hypertension, hypercholesterolaemia, family
history of MI and smoking. In multivariate analysis
only age (OR=1.06 95% CI 1.03 to 1.09),
hypertension (OR=5.01, 95% CI 1.38 to 18.23),
hypercholesterolaemia (OR=4.43, 95% CI 1.51 to
12.99) and smoking (OR=7.50, 95% CI 2.38 to 23.57)
remained significant risk factors.
Conclusions: In some patients with lupus, MI may
develop even before the diagnosis of SLE or shortly
thereafter, suggesting that there may be a link
between autoimmune inflammation and
atherosclerosis.
INTRODUCTION
Survival in systemic lupus erythematosus
(SLE) has improved significantly over the
past four decades.1 2 Nevertheless, the mor-
tality risk in SLE remains three times that of
the general population. The major causes of
death remain active lupus, infection and car-
diovascular disease.2 3 It has long been
known that mortality patterns in SLE have
suggested that early deaths are due to lupus
and infection, whereas late deaths are often
associated with cardiovascular disease.4
Indeed, cardiovascular disease has been
recognised as a major morbidity among
patients with SLE.1 5–7 The prevailing
concept has been that atherosclerosis devel-
ops prematurely among patients with SLE in
the setting of chronic inflammatory disease,
with a contribution from increased trad-
itional cardiovascular risk factors. Similar
observations have been made in a number of
inflammatory musculoskeletal diseases such
as rheumatoid arthritis8 and psoriatic arth-
ritis.9 10 Recently, Pahau et al11 reported
increased prevalence of cardiovascular
disease prior to the onset of rheumatoid
arthritis. Bartels et al12 observed an excess of
cardiovascular events in the 2 years prior to
the diagnosis of SLE in an analysis of a US
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population-based study and suggested that this may be
due to either delayed SLE diagnosis or actual acceler-
ated cardiovascular disease prior to SLE.
The systemic lupus international collaborating clinics
(SLICC) group has developed an international registry
of newly diagnosed (within 15 months of diagnosis)
patients with SLE to carry out a prospective, longitudinal
study to determine the incidence, prevalence and
nature of atherosclerotic coronary artery disease (CAD)
in SLE, to identify associated risk factors for the develop-
ment of CAD and its outcomes and to discern the con-
tribution of disease and therapy to the occurrences of
these risk factors.13–15 In the course of observation of
this SLICC cohort, atherosclerotic cardiovascular events
were identified either prior to the diagnosis of SLE or
soon thereafter. The aim of this study was to examine
the frequency of myocardial infarction (MI) prior to the
diagnosis of SLE and within the first 2 years of follow-up.
METHODS
The SLICC group includes investigators interested in
the study of outcomes in SLE and comprises 33 centres
from 11 countries, in North America, Europe and
Asia.13–15 An inception cohort of patients with SLE has
been assembled and followed at yearly intervals accord-
ing to a standardised protocol between 2000 and 2014.
Sample size calculation at the initiation of the cohort
suggested that 1800 patients would suffice to identify
CAD events even allowing for loss to follow-up. Patient
accrual occurred from 2000 to 2011.
Patient selection
Patients are eligible to enter the cohort within
15 months of SLE diagnosis, which is determined when
a patient has achieved four or more American College
of Rheumatology (ACR) criteria for the classification of
SLE.16 All patients consented to participate in the study
which was approved by the local institutional ethic boards.
Assessments
Clinical and laboratory features of SLE and
co-morbidities, including CAD risk factors, are recorded
in a standardised protocol at yearly intervals.
Hypertension is defined as elevated blood pressure
>140/90 mm Hg or receiving antihypertensive therapy.
Hypercholesterolaemia is defined as total cholesterol
>5.2 mmol/L or receiving hyperlipidaemia therapy.
Vascular events including MI are described and attribu-
ted on a specialised form.14 15
Event diagnosis
MI diagnosis was based on the MONICA (MONItoring
of Trends and Determinants in CArdiovascular Disease)
criteria defined as by ‘(a) definite ECG or (b)
Symptoms typical or atypical or inadequately described,
together with probable ECG and abnormal enzymes, or
(c) Symptoms typical and abnormal enzymes with
ischemic or noncodable ECG’.17 The diagnosis was
often supported by abnormal stress test, abnormal echo-
cardiogram, abnormal nuclear scan and abnormal
angiogram as reported by the treating institution. We
also looked at the occurrence of angina defined by the
MONICA criteria as severe pain or discomfort over the
upper or lower sternum or anterior left chest and left
arm and diagnosed by the clinician as angina and attrib-
uted to atherosclerosis (not associated with active
lupus).17 Since the SLICC cohort began in 2000, these
criteria were adopted prior to the universal definition of
MI criteria,18 but were based on the MONICA criteria.17
Ascertainment of previous events
Events were self-reported and validated from medical
records using the criteria listed above.
Statistical analysis
Descriptive statistics and multivariate logistic regression
analysis were used to compare the characteristics of
patients with and without MI, using SAS V.9.3. Variables
that reached statistical significance in the univariate ana-
lysis were included in the regression model. The preva-
lence of MI in the SLICC cohort between the ages 40
and 49 was compared with the prevalence of self-
reported MI in the province of Ontario.
RESULTS
Between 2000 and 2014, 1848 patients were entered into
the cohort with a mean follow-up of 8.9±3.3 years. There
were 1640 females (88.8%), with a mean age at diagno-
sis of 34.7±13.3 years and mean disease duration at entry
to the cohort of 5.6±4.2 months.
Thirty-one of 1848 patients had an MI. Of those, 23
patients had an MI either prior to SLE diagnosis or
within the first 2 years of disease. Of the 23 patients
studied, 14 were female, 18 were Caucasian, 2 African
descendants, 2 Hispanic and 1 other. The mean age at
SLE diagnosis was 52.5±15.0 years, and the mean age at
MI was 49.3±13.4 years (table 1). Of the 23 MIs, 16
occurred at a mean of 6.1±7.0 years prior to diagnosis
and 7 occurred within the first 2 years of follow-up
(figure 1). Of the six patients with MI five or more years
prior to the SLE diagnosis, three were female, five were
Caucasian, the mean age at MI was 49.1 (±9) years and
the mean age at SLE diagnosis was 64.5 (±9.2) years.
There were no demographic differences between patients
who had an MI before (16) and after (7) SLE diagnosis.
The demographic and disease characteristics of the 23
patients with an early MI were compared with those who
did not have an MI within the SLICC inception cohort
(table 1). Coronary artery risk factors found more fre-
quently in those with an early MI were male sex,
Caucasian ethnicity, older age at diagnosis, family history
of all MIs (not necessarily premature), hypertension,
hypercholesterolaemia, smoking and lower SLEDAI-2K
at inception. There was no difference in organ
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involvement between the two groups. In addition, there
was no difference in serological manifestations including
positive anti-DNA, low complement or the presence of
anticardiolipin antibodies or the lupus anticoagulant at
inception. High sensitivity C reactive protein and
erythrocyte sedimentation rate were similar between the
two groups at inception. Use of corticosteroids, antima-
larials and immunosuppressive medications was similar
between the two groups at inception (table 1).
In a logistic regression analysis, risk factors associated
with early MI in univariate analysis were male sex
(OR=5.25, 95% CI 2.25 to 12.29), Caucasian race
(OR=3.77, 95% CI 1.39 to 10.19), age (OR=1.08, 95% CI
1.05 to 1.11), family history of MI (OR=2.02, 95% CI 1.03
to 3.99), hypertension (OR=7.55, 95% CI 2.56 to 22.27),
hypercholesterolaemia (OR=5.91, 95% CI 2.17 to 16.10)
and smoking ever (OR=6.85, 95% CI 2.53 to 18.52).
Multivariate analysis revealed that only age (OR=1.06 95%
CI 1.03 to 1.09), hypertension (OR=5.09, 95% CI 1.34 to
18.23), hypercholesterolaemia (OR=4.43, 95% CI 1.51 to
12.99) and smoking (OR=7.50, 95% CI 2.38 to 23.57) were
independent risk factors for the development of early MI
after controlling SLEDAI-2K, low complement and corti-
costeroids in the model (table 2).
Table 1 Cohort characteristics and coronary artery disease risk factors at baseline
MI before or shortly after SLE
Patients (n=23)
No MI
Patients (n=1825) p Value
Sex (F) 14 (60.9%) 1626 (89.1%) <0.001
Caucasian 18 (78.3%) 879 (48.5%) 0.005
Mean age at SLE diagnosis
Mean age at MI diagnosis
52.5±15.0
49.3±13.4
34.5±13.2
NA
<0.001
NA
SLE duration in months 5.6±4.2 6.1±4.5 0.547
SLEDAI-2K 3.7±3.5 5.4±5.4 0.03
Hypercholesterolaemia 17 (73.9%) 652 (35.7%) <0.001
Hypertension 19 (82.6%) 705 (38.6%) <0.0001
BP diastolic 74.2±12.2 75.2±11.0 0.67
BP systolic 125.8±18.5 119.6±16.8 0.07
Diabetes 1 (4.6%) 68 (3.7%) 0.34
Metabolic syndrome 5/19 (26.3%) 238/1638 (13.0%) 0.18
Family history of MI* 9/23 (39.1%) 264/1752 (55.3%) 0.008
Smoking ever 18/23 (78.3%) 629/1185 (34.6%) 0.001
Anti-dsDNA antibodies 7/22 (31.8%) 650/1660 (39.1%) 0.57
Low complement components 3 and 4 8/22 (36.4%) 617/1662 (37.1%) 0.76
High sensitivity C reactive protein 7/16 (43.8%) 298/1263 (23.5%) 0.06
Erythrocyte sedimentation rate 8/14 (57.1%) 519/928 (55.9%) 0.91
Anticardiolipin antibodies 1.47±6.06 10.42±83.23 0.66
Lupus anticoagulant 3/17 (17.7%) 249/1190 (20.9%) 1.00
Corticosteroids 19 (82.6%) 1260 (69.0%) 0.16
Antimalarials 14 (60.9%) 1233 (67.7%) 0.75
Immunosuppressives 10 (43.5%) 723 (40.0%) 0.91
Bold text indicates significant findings.
*Inclusive of all MIs and not limited to premature MIs.
BP, blood pressure; MI, myocardial infarction; NA, not applicable; SLE, systemic lupus erythematosus.
Figure 1 23 myocardial
infarction (MI) events occurred
prior to or in the first 2 years in
1848 patients. Age at MI is
indicated by the number below
each bar.
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There were 17 patients with a history of MI within
5 years prior to diagnosis or within the first 2 years after
diagnosis of SLE whose mean age was 48 years at MI.
Therefore, the prevalence of MI in the SLICC cohort
between the ages 40 and 49 (17/325) was 4.8% com-
pared with the province of Ontario in Canada in a popu-
lation of 5 077 402 at ages 40–49 of 0.7%.19
We then examined the frequency of angina due to
atherosclerosis. Fifteen patients were diagnosed with
angina (without MI) and of these five developed the
angina within the first 2 years of SLE at a mean age of
51.0±17.6 years.
DISCUSSION
Atherosclerotic disease is an important cause of morbid-
ity and mortality among patients with SLE. Previous
studies have concentrated on cardiovascular events
occurring after the diagnosis of SLE. The prevalence of
symptomatic CAD in established lupus cohorts varies
from 8.3% in Baltimore, 6.6% in Pittsburgh and 8.9% in
Toronto.1 5 6 The mean age at first CAD event is similar
in the three cohorts at 48–49 years. In a community-
based cohort using the California Discharge Database,
Ward showed that women with SLE between 18 and
44 years of age were more likely than age-matched con-
trols to be admitted to hospital with MI.20 Incidence
rates of CAD in women with lupus are significantly
raised compared with age-matched controls. Women
with lupus aged 35–44 were 50 times more likely to
have an MI compared with age-matched women.5 The
rate of MI in the Toronto lupus cohort was five times
higher than the general population. Furthermore, the
mean age of MI in the Toronto lupus cohort was
49 years compared with the peak years of the general
population of 65–74 years.21 In addition, Esdaile has
shown that traditional Framingham risk factors fail to
fully account for the accelerated atherosclerosis in
patients with SLE.22
These studies indicate that women with SLE have a sig-
nificantly increased risk for MI, the onset of the CAD is
premature and that lupus itself is an important asso-
ciated factor. In a study of the natural history of hyper-
cholesterolaemia in an inception cohort (within
12 months of diagnosis) of patients with SLE, Bruce
et al23 reported that time to event in patients who had a
CAD-related event was 7.5 years from diagnosis of SLE.
Until recently, there has been little attention to
cardiac events occurring either prior to SLE or early in
the course of the disease. In a large US study of mortal-
ity and cardiovascular burden in SLE, Bartels et al12
found that prior cardiovascular disease events in the
2 years preceding diagnosis of SLE occurred in 23% of
70 patients compared with 10% of 2565 aged and sex-
matched controls (p<0.05).
The SLICC atherosclerosis registry, which is an incep-
tion cohort within 15 months of diagnosis, allows identi-
fication of atherosclerotic events early in the course of
the disease. The current study demonstrates that clinical
cardiovascular events may occur prior to or early after
the diagnosis of lupus. Of the 1848 patients followed in
the SLICC cohort, there were 23 MIs that occurred prior
to or within the first 2 years of disease. The prevalence
of this occurrence in the SLICC cohort patients aged
40–49 was higher than the self-reported prevalence of
MI in Canadian Community Health Survey conducted
in Ontario of similar age (4.8% vs 0.7%, respectively).19
Self-reported incidence of MI tends to be over-reported
as compared with the prevalence from administrative
data and therefore makes the significance of MI preva-
lence in the SLICC cohort greater.24 In addition, five
instances of angina without MI were documented within
the same time frame and are at risk for developing MI
later in their course.
Table 2 Multivariable logistic regression for the outcome
of early myocardial infarction
Predictors OR
Lower
95%
CI for
OR
Upper
95%
CI for
OR p Value
Age at systemic lupus
erythematosus diagnosis
1.06 1.03 1.09 <0.0006
SLEDAI-2K 0.87 0.76 1.00 0.057
Hypertension 5.09 1.38 18.23 0.0145
Low complement 2.34 0.78 7.04 0.131
Corticosteroids 2.42 0.76 7.69 0.135
Hypercholesterolaemia 4.43 1.51 12.99 0.0068
Smoking ever 7.50 2.38 23.57 0.0006
*Variable selection: started with all variables, step down
eliminating variables with highest p value until smallest Akaike
Information Criterion (AIC) was reached.
Figure 2 Evolution of benign
autoimmunity and early
atherosclerosis to clinical disease.
SLE, systemic lupus
erythematosus.
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Our study indicates that older males diagnosed with
lupus are most at risk for developing MIs early in the
course of their lupus. It is interesting that anticardiolipin
antibodies, lupus anticoagulant and family history of all
MIs at inception were not significantly associated factors
in the multivariate analysis.
A limitation of our study is that the universal defin-
ition of MI criteria was not available at the time our
cohort was developed. However, we did use the WHO
criteria that were available at the time. Moreover, since
the cohort was created to discern atherosclerotic cardio-
vascular events in patients with lupus, the investigators
excluded the possibility of lupus disease activity (eg,
pericarditis, myocarditis, vasculitis and pleurisy) when
attributing an event to atherosclerosis.
These findings raise the question as to the relationship
between atherosclerotic events and SLE. For atheroscler-
osis and SLE, the clinical event is obviously preceded by
pathogenic mechanisms over a few years. It has been
shown that autoantibodies develop in patients with SLE
many years before the clinical recognition of the
disease.25 This could lead to subclinical autoimmunity
which subsequently manifests as a clinical diagnosis of
SLE (figure 2). Similarly, inflammatory and metabolic
mechanisms develop in patients with atherosclerosis
before any evidence for clinical disease (MI, angina).26
It is therefore possible that subclinical autoimmunity
may result in subclinical atherosclerosis and either can
manifest itself clinically as the initial clinical presenta-
tion.27 Alternatively, the two mechanisms, autoimmunity
and atherosclerosis, may develop independently but con-
currently and may manifest themselves clinically at dif-
ferent times. This may be due to either a common
genetic predisposition to both conditions or independ-
ent genetic factors interacting through epigenetic or
environmental influences.
Our study highlights the possible relationship between
immunologic and inflammatory mechanisms leading to
both SLE and atherosclerosis. Thus, the physician caring
for patients with SLE must be aware that these patients
require careful investigation and treatment of cardiovas-
cular risk factors. Also, physicians caring for patients
with premature atherosclerotic disease should consider
the possibility of an increased risk of autoimmune
disease and consider investigating such patients for
‘benign autoimmunity’ that is the presence of autoanti-
bodies in the absence of any clinical disease with an
autoantibody screen.
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